未登录The impact of high-risk cytogenetic abnormalities in extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study
Liang, Dong; Yan, Yurong; Bai, Shenrui; Xu, Weiling; Wang, Qiaoli; Feng, Demei; Zeng, Min; Nie, Xiaomiao; Feng, Yuan; Chen, Xiaoqin; Xia, Zhongjun; Liang, Yang; Jin, Fengyan; Wang, Hua .png)
分享.png)
收藏Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients with Newly Diagnosed Multiple Myeloma (NDMM): Insights from a Multi-Center Study新型药物时代诱导治疗的临床结局及高危细胞遗传学异常(HRA)数量对新诊断多发性骨髓瘤(NDMM)患者预后的影响：多中心研究的启示Liang, Dong; Feng, Demei; Wang, Qiaoli; Bai, Shenrui; Zeng, Min; Lu, Bo; Li, Xiaoqing; Sun, Zhiqiang; Li, Jianyun; Zhou, Huanhuan; Zhang, Jialu; Chen, Xiaoqin; Xia, Zhongjun; Liang, Yang; Wang, Hua 分享 收藏 Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myelomaLiang, Dong; Bai, Shenrui; Feng, Demei; Chen, Guanjun; Liang, Yang; Wang, Hua 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png)
BLOOD.png)
